Ophthalmology Times

SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Design Week

Canva makes pro design tool Affinity “free, forever”

Canva is making its professional design tool Affinity “free forever” in a bid to upend the design software market. The ...